Behbood Sadrolhefazi, MD

Director, Clinical Program Leader/Oncology
Boehringer Ingelheim Pharmaceuticals, Inc.

Poster(s):

• (299) Patient-reported outcomes evaluating physical functioning and symptoms in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non-small cell lung cancer - results from the Beamion LUNG-1 trial
  Wednesday, October 29, 2025

• (301) Zongertinib in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non–small cell lung cancer: Beamion LUNG-1
  Wednesday, October 29, 2025